Clover Corporation Limited · ASX:CLV

Clover — Shareholder Meeting (November 2026)

38 slides from Clover's shareholder meeting presentation, Nov 17, 2026

  1. Slide 1: FY26 Annual General Meeting

    rsonal use only FY26 Annual General Meeting 17 November 2026 Chair Rupert Harrington CEO Peter Davey

  2. Slide 2: Welcome

    Clover rsonal use only Corporation Limited Welcome FY26 Annual General Meeting 2

  3. Slide 3: Board members

    Board members rsonal use only Rupert Harrington Peter Davey Toni Brendish Chair Managing Director & CEO Non-Executive Director Brett Hewlett Dr. Simon Green Ian Glasson Fiona Pearse Non-Executive Director Non-Executive Director Non-Executive Director Non-Executive Director 3

  4. Slide 4: Agenda

    Agenda Formal business rsonal use only 02 Welcome 24 Item 1 – Adoption of annual accounts 03 Introductions 25 Item 2 – Resolution 1: Adoption of remuneration report 05 How to ask questions 26 Item 3 – Resolution 2: Re-election of Mr. Ian Glasson 06 How to vote 28 Item 4 – Resolution 3: Re-election o

  5. Slide 5: How to ask a question

    How to ask a questions • To ask a written question select rsonal use only the Q&A icon • Select the topic your question relates to from the drop-down list • Type your question in the text box and press the send button • To ask a verbal question follow the instructions below the broadcast window. 5

  6. Slide 6: How to vote

    How to vote • When the poll is open, select the rsonal use only vote icon at the top of the screen • To vote, select either For, Against or Abstain • You will see a vote confirmation • To change or cancel your vote, “click here to change your vote” at any time until the poll is closed 6

  7. Slide 7: Chairman's Address

    rsonal use only Chairman’s Address

  8. Slide 8: Managing Director's Presentation on FY26 Results

    rsonal use only Managing Director’s Presentation on FY26 Results 8

  9. Slide 9: FY26 Financial Highlights

    FY26 Financial Highlights Strong performance underpinned by adherence to long-term growth strategy rsonal use only $97.4m 35.5% Revenue ahead of guidance for $92-96m and up 13% on FY25 $86m. Gross margin improvement driven by innovation, product mix and increased benefits from vertical integration R

  10. Slide 10: Operational Highlights – FY26

    Operational Highlights – FY26 rsonal use only o Higher demand from infant o CholineXcel – patent has formula customers for Clover’s been registered and high-quality ARA powders. commercial packaging options are being o Melody Dairies delivering profit developed. margin benefits in line with expectat

  11. Slide 11: Product Mix: Successful diversification from innovation

    Product Mix: Successful diversification from innovation rsonal use only FY26 o Western manufacturers continue to increase market share o New product sales driven by customer and product diversification o Increased demand for ARA products FY25 o 1H market demand – western manufacturers increased mark

  12. Slide 12: Financials

    rsonal use only Financials 12

  13. Slide 13: Profit and Loss FY26

    Profit and Loss FY26 FY26 FY25 Profit & Loss Highlights Change rsonal use only $M $M o Revenue increased 13% driven by strong growth in ANZ and EU that more than offset declines in Asia and Americas. Revenue ($m) $97.4 $86.0 +13.3% o The gross profit margin increased to 35.5%, the positive result re

  14. Slide 14: Balance Sheet July 2026

    Balance Sheet 31 July 2026 FY26 FY25 Change Balance Sheet rsonal use only $M $M $M o Strong cash position maintained, reflecting the ongoing investment in inventory (+$19.8m in Cash 7.2 8.7 (1.5) FY26) that was partly offset by improved earnings performance and a more modest Trade Receivables 17.3 2

  15. Slide 15: Operational Highlights

    rsonal use only Operational Highlights 15

  16. Slide 16: Ecuador facility: Sustainable Fish Oil Extraction

    Ecuador facility: Sustainable Fish Oil Extraction rsonal use only Investment in crude fish oil supply chain is contributing to profit margins gains, with tuna oil steady at 30% of total raw material inputs in FY26. o Continuing to negotiate additional supply of high quality tuna heads. o Weather pat

  17. Slide 17: New Zealand: processing and encapsulating of oils

    New Zealand: processing and encapsulating of oils rsonal use only Melody Dairies facility Delivering high-quality Melody Dairies is Weekly use by Clover in Pursuing opportunities products with improved operating at near full manufacturing product to maximise outputs to plant use and efficiency capac

  18. Slide 18: CholineXcel

    CholineXcel TM o CholineXcel is a unique flowable powder that has broad based rsonal use only commercial applications, with near-term focus on the infant formula and nutraceutical market. o Samples have been presented to selected customers. o Intellectual Property process continues to advance, with

  19. Slide 19: DHA & ARA Growth

    DHA & ARA Growth rsonal use only DHA Growth (Omega 3) ARA Growth (Omega 6) • Product diversification into non- • Higher demand from infant formula allergenic, higher fortification levels customers for Clover’s high-quality and plant-based powders have ARA powders allowed Clover to deliver new soluti

  20. Slide 20: USA Nutraceutical Market Development

    USA USNutraceutical Market nutraceuticals market an emerging Development focus rsonal use only US is the world’s largest nutraceuticals market Clover to use nutraceuticals to spearhead US growth Continued diversification of nutraceuticals formats is positive for Clover’s encapsulation technologies a

  21. Slide 21: Strategy and outlook

    rsonal use only Strategy and outlook 21

  22. Slide 22: Strategic focus

    Strategic focus 1 Choline – market release, customer acceptance & initial orders & scaled manufacturing and certification rsonal use only 2 USA nutraceutical market development 3 Continued development of our distributor network 4 Investment in facilities & people 5 Continue focused innovation to fur

  23. Slide 23: FY27 Outlook

    FY27 Outlook rsonal use only Clover enters FY27 with positive momentum supported by continued demand for its nutritional products, the benefits of a vertically integrated high- quality supply chain and further expansion of its distribution network. These factors with product mix are contributing to

  24. Slide 24: Disclaimer

    Disclaimer The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe such rsonal use only re

  25. Slide 25: Formal Business

    rsonal use only Formal Business 25

  26. Slide 26: Adoption of annual accounts

    rsonal use only 01 Adoption of annual accounts 26

  27. Slide 27: Resolution 1: Adoption of remuneration report

    rsonal use only 02 Resolution 1: Adoption of remuneration report 27

  28. Slide 28: Remuneration Report proxy votes

    rsonal use only For Voted 61,544,202 % 82.87 Resolution 1 Against 173,976 0.23 Open-Usable Abstain 12,546,733 232,160 16.90 N/A Remuneration Report Excluded 1,201,260 N/A 100.0 Proxy Votes 28

  29. Slide 29: Resolution 2: Re-election of Mr. Ian Glasson

    rsonal use only 03 Resolution 2: Re-election of Mr. Ian Glasson 29

  30. Slide 30: Re-elect Mr. Ian Glasson proxy votes

    rsonal use only Resolution 2 Voted % For 60,628,268 80.37 Against 2,251,729 2.99 Re-elect Mr. Ian Glasson Open-Usable 12,546,733 16.64 Abstain 211,601 N/A Proxy Votes Excluded 60,000 N/A 100.0 30

  31. Slide 31: Resolution 3: Re-election of Ms. Toni Brendish

    rsonal use only 04 Resolution 3: Re-election of Ms. Toni Brendish 31

  32. Slide 32: Re-elect Ms. Toni Brendish proxy votes

    rsonal use only Resolution 3 Voted % For 62,910,985 83.33 Against 26,460 0.04 Re-elect Ms. Toni Brendish Open-Usable 12,550,733 16.63 Abstain 210,153 N/A Proxy Votes Excluded - N/A 100.0 32

  33. Slide 33: Resolution 4: Election of Mr. Brett Hewlett

    rsonal use only 05 Resolution 4: Election of Mr. Brett Hewlett 33

  34. Slide 34: Elect Mr. Brett Hewlett proxy votes

    rsonal use only Voted % Resolution 4 For 60,700,973 80.40 Against 2,239,192 2.97 Open-Usable 12,546,033 16.63 Elect Mr. Brett Hewlett Abstain 212,133 N/A Excluded - N/A 100.0 Proxy Votes 34

  35. Slide 35: Resolution 5: Approve acquisition of performance rights by the Managing Director

    rsonal use only 06 Resolution 5: Approve acquisition of performance rights by the Managing Director 35

  36. Slide 36: Performance Rights proxy votes

    rsonal use only Resolution 5 Voted % For 59,970,209 80.10 Performance Rights Against Open-Usable 2,354,535 12,546,033 3.14 16.76 Managing Director Abstain 827,554 N/A Excluded - N/A 100.0 Proxy Votes 36

  37. Slide 37: Voting poll & close

    rsonal use only Voting poll & close 37

  38. Slide 38: Questions

    rsonal use only Questions 38

Clover — Shareholder Meeting (November 2026) on 6ix